Skip to search formSkip to main contentSkip to account menu

naptumomab estafenatox

A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal… 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (1)

ABR-217620

Broader (3)

EnterotoxinsImmunoconjugatesMonoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Purpose: To prospectively determine the efficacy of naptumomab estafenatox (Nap) + IFNα versus IFN in metastatic renal cell… 
2015
2015
Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α
Naptumomab estafenatox/ABR-217620/ANYARA (Nap) has been evaluated in clinical phase 1 and 2/3 studies. RCC patients in the phase… 
Review
2014
Review
2014
Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
Improvement of cancer therapy by introducing new concepts is still urgent even though there have been major advancements lately… 
Review
2013
Review
2013
Which are the antibodies to watch in 2013?
The start of the new year signals that it is time for mAbs’ annual review of the therapeutic monoclonal antibodies (mAbs) in… 
Review
2013
Review
2013
Antibodies to watch in 2013
The transitions of antibody therapeutics to late-stage clinical development, regulatory review and the market are proceeding at a… 
Review
2011
Review
2011
Antibody-based therapeutics to watch in 2011
This overview of 25 monoclonal antibody (mAb) and 5 Fc fusion protein therapeutics provides brief descriptions of the candidates… 
2010
2010
Naptumomab Estafenatox, an Engineered Antibody-superantigen Fusion Protein With Low Toxicity and Reduced Antigenicity
Antibody-targeted superantigens have a potential to become useful drugs for tumor therapy. However, clinical practice has… 
Review
2010
Review
2010
Naptumomab estafenatox: a new immunoconjugate
Importance of the field: New agents that specifically engage the immune system are being tested in a variety of malignancies… 
Highly Cited
2010
Highly Cited
2010
Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials
Traditionally, the major objective in phase I trials is to identify a working-dose for subsequent studies, whereas the major… 
Highly Cited
2009
Highly Cited
2009
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung…
PURPOSE Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License